Stakeholders' Perspectives on Current Issues in Data Monitoring Committees

ABSTRACT Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are wi...

Full description

Saved in:
Bibliographic Details
Published inBiometrical journal Vol. 66; no. 7; pp. e202300384 - n/a
Main Authors Cartwright, Michael J., Friede, Tim, Lawrence, David, May, Emma, Mütze, Tobias, Roes, Kit
Format Journal Article
LanguageEnglish
Published Germany Wiley - VCH Verlag GmbH & Co. KGaA 01.10.2024
Subjects
Online AccessGet full text
ISSN0323-3847
1521-4036
1521-4036
DOI10.1002/bimj.202300384

Cover

Abstract ABSTRACT Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC—We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions—We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data—We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays—We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality.
AbstractList Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC-We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions-We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data-We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays-We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality.
ABSTRACT Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC—We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions—We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data—We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays—We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality.
Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC-We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions-We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data-We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays-We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality.Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC-We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions-We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data-We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays-We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality.
Author Cartwright, Michael J.
Friede, Tim
Roes, Kit
Mütze, Tobias
Lawrence, David
May, Emma
Author_xml – sequence: 1
  givenname: Michael J.
  orcidid: 0009-0008-2765-1571
  surname: Cartwright
  fullname: Cartwright, Michael J.
  email: michael.cartwright@parexel.com
  organization: Parexel International Ltd
– sequence: 2
  givenname: Tim
  orcidid: 0000-0001-5347-7441
  surname: Friede
  fullname: Friede, Tim
  organization: DZHK (German Center for Cardiovascular Research)
– sequence: 3
  givenname: David
  surname: Lawrence
  fullname: Lawrence, David
  organization: Novartis Pharma AG
– sequence: 4
  givenname: Emma
  surname: May
  fullname: May, Emma
  organization: BioNTech SE
– sequence: 5
  givenname: Tobias
  orcidid: 0000-0002-4111-1941
  surname: Mütze
  fullname: Mütze, Tobias
  organization: Novartis Pharma AG
– sequence: 6
  givenname: Kit
  orcidid: 0000-0002-6775-1963
  surname: Roes
  fullname: Roes, Kit
  organization: Radboud University Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39308116$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1PGzEQhi2UigTKlSNaqQe4bBh_xLs-tgHaREFUajlb3l0vOOzaqe0F8e8xChQJCXGZkUbPMxrNu4dG1lmN0CGGKQYgp5Xp11MChALQku2gCZ4RnDOgfIQmQAnN07gYo70Q1gAggJFdNKaCQokxn6Dln6ju9K3rGu3DcfY71Y2uo7nXIXM2mw_eaxuzRQhDmhibnamosktnTXTe2Jts7vrexKh1-Iq-tKoL-uCl76Pri_O_81_56urnYv59ldcMU5Y3uCVMCD3jApQqcFuUVcs4UbrkuCkwrcqihrbiomFckUoo1paiojWjQnDO6D462e7dePcvXRVlb0Ktu05Z7YYgKYaSlqKY8YR-e4eu3eBtui5RmBczUVCcqKMXaqh63ciNN73yj_L1SwlgW6D2LgSvW1mbqKJxNnplOolBPochn8OQ_8NI2vSd9rr5Q0FshQfT6cdPaPljcbl8c58AtTeasA
CitedBy_id crossref_primary_10_1007_s43441_024_00720_8
Cites_doi 10.1007/s43441‐023‐00499‐0
10.1056/NEJMra1510066
10.1177/1740774518764855
10.1177/2168479018754846
10.3310/hta9070
10.1177/1740774518764449
10.1201/9781315181608
10.1177/1740774516688915
10.1016/j.cct.2020.106154
10.1177/2168479017739268
10.1177/1740774517707743
10.1056/NEJMsb1601674
10.7326/M19‐1491
10.1002/0470854162
10.1002/sim.1791
10.1109/VL.1996.545291
10.1001/jama.2016.16070
10.1080/19466315.2020.1736142
10.1056/evidctw2200220
10.1056/evidctw2100005
10.1080/10543406.2014.925719
10.1186/s13063‐023‐07290‐4
ContentType Journal Article
Copyright 2024 Wiley‐VCH GmbH.
Copyright_xml – notice: 2024 Wiley‐VCH GmbH.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
8FD
FR3
K9.
P64
7X8
DOI 10.1002/bimj.202300384
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE

ProQuest Health & Medical Complete (Alumni)
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1521-4036
EndPage n/a
ExternalDocumentID 39308116
10_1002_bimj_202300384
BIMJ202300384
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
-~X
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
23N
3-9
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACIWK
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AI.
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
DUUFO
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M67
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TN5
UB1
V2E
VH1
W8V
W99
WBKPD
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRC
WUP
WWH
WXSBR
WYISQ
XBAML
XG1
XPP
XV2
Y6R
YHZ
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
AMVHM
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
FR3
K9.
P64
7X8
ID FETCH-LOGICAL-c4134-d1f2499e5690aa71f78bf462ae861d713b87c0fb69d46a2b9a4f89b3c43996643
IEDL.DBID DR2
ISSN 0323-3847
1521-4036
IngestDate Thu Jul 10 22:23:15 EDT 2025
Fri Jul 25 19:18:57 EDT 2025
Thu Apr 03 07:07:08 EDT 2025
Thu Apr 24 23:05:26 EDT 2025
Tue Jul 01 04:18:08 EDT 2025
Wed Jan 22 17:15:50 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords benefit‐risk
patient safety
data monitoring committee
study integrity
Language English
License 2024 Wiley‐VCH GmbH.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4134-d1f2499e5690aa71f78bf462ae861d713b87c0fb69d46a2b9a4f89b3c43996643
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-6775-1963
0009-0008-2765-1571
0000-0002-4111-1941
0000-0001-5347-7441
OpenAccessLink https://resolver.sub.uni-goettingen.de/purl?gro-2/145835
PMID 39308116
PQID 3116759731
PQPubID 105592
PageCount 13
ParticipantIDs proquest_miscellaneous_3108389756
proquest_journals_3116759731
pubmed_primary_39308116
crossref_citationtrail_10_1002_bimj_202300384
crossref_primary_10_1002_bimj_202300384
wiley_primary_10_1002_bimj_202300384_BIMJ202300384
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2024
2024-10-00
2024-Oct
20241001
PublicationDateYYYYMMDD 2024-10-01
PublicationDate_xml – month: 10
  year: 2024
  text: October 2024
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Weinheim
PublicationTitle Biometrical journal
PublicationTitleAlternate Biom J
PublicationYear 2024
Publisher Wiley - VCH Verlag GmbH & Co. KGaA
Publisher_xml – name: Wiley - VCH Verlag GmbH & Co. KGaA
References 2021; 13
2023; 57
2023; 24
2017; 14
2020
2016; 316
2005; 9
2004; 23
2020; 172
2016; 375
1996
2006
2014; 24
2016; 374
2018; 52
2016
2005
2022; 1
2023; 2
2002
2020; 98
2013
2024
2018; 15
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 24
  start-page: 289
  issue: 1
  year: 2023
  article-title: DMC Reports in the 21st Century: Towards Better Tools for Decision‐Making
  publication-title: Trials
– volume: 24
  start-page: 968
  issue: 5
  year: 2014
  end-page: 975
  article-title: Enhancing Trial Integrity by Protecting the Independence of Data
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 172
  start-page: 119
  issue: 2
  year: 2020
  end-page: 125
  article-title: Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job
  publication-title: Annals of Internal Medicine
– volume: 15
  start-page: 321
  issue: 4
  year: 2018
  end-page: 328
  article-title: Data Monitoring Committees: Current Issues
  publication-title: Clinical Trials
– volume: 98
  year: 2020
  article-title: Data Monitoring Committees for Clinical Trials Evaluating Treatments of COVID‐19
  publication-title: Contemporary Clinical Trials
– year: 2005
– volume: 57
  start-page: 515
  issue: 3
  year: 2023
  end-page: 520
  article-title: Challenges in Implementing Futility Schemes, With Reference to Aducanumab
  publication-title: Therapeutic Innovation & Regulatory Science
– volume: 9
  start-page: 1
  issue: 7
  year: 2005
  end-page: 238
  article-title: Issues in Data Monitoring and Interim Analysis of Trials
  publication-title: Health Technology Assessment
– year: 2024
– volume: 316
  start-page: 2359
  issue: 22
  year: 2016
  end-page: 2360
  article-title: Enhancing the Scientific Integrity and Safety of Clinical Trials
  publication-title: JAMA
– volume: 52
  start-page: 459
  issue: 4
  year: 2018
  end-page: 468
  article-title: Reports to Independent Data Monitoring Committees
  publication-title: Therapeutic Innovation & Regulatory Science
– volume: 13
  start-page: 355
  issue: 3
  year: 2021
  end-page: 366
  article-title: Clinical Trial Drug Safety Assessment With Interactive Visual Analytics
  publication-title: Statistics in Biopharmaceutical Research
– year: 2016
– start-page: 336
  year: 1996
  end-page: 343
  article-title: The Eyes Have It: A Task by Data Type Taxonomy of Information Visualizations
– volume: 374
  start-page: 1580
  issue: 16
  year: 2016
  end-page: 1584
  article-title: Challenges to Data Monitoring Committees When Regulatory Authorities Intervene
  publication-title: The New England Journal of Medicine
– volume: 375
  start-page: 1365
  issue: 14
  year: 2016
  end-page: 1371
  article-title: Data Monitoring Committees—Expect the Unexpected
  publication-title: New England Journal of Medicine
– volume: 14
  start-page: 115
  issue: 2
  year: 2017
  end-page: 123
  article-title: Data Monitoring Committees: Promoting Best Practices to Address Emerging Challenges
  publication-title: Clinical Trials: Journal of the Society for Clinical Trials
– year: 2002
– year: 2006
– year: 2020
– volume: 2
  issue: 2
  year: 2023
  article-title: The Data and Safety Monitoring Board: The Toughest Job in Clinical Trials
  publication-title: NEJM Evidence
– volume: 1
  issue: 1
  year: 2022
  article-title: Independent Oversight of Clinical Trials Through Data and Safety Monitoring Boards
  publication-title: NEJM Evidence
– volume: 52
  start-page: 696
  issue: 6
  year: 2018
  end-page: 700
  article-title: The Safety Explorer Suite: Interactive Safety Monitoring for Clinical Trials
  publication-title: Therapeutic Innovation & Regulatory Science
– volume: 23
  start-page: 1535
  issue: 10
  year: 2004
  end-page: 1539
  article-title: A Major Trial Needs Three Statisticians: Why, How and Who?
  publication-title: Statistics in Medicine
– volume: 14
  start-page: 342
  issue: 4
  year: 2017
  end-page: 348
  article-title: Recommendations for Data Monitoring Committees From the Clinical Trials Transformation Initiative
  publication-title: Clinical Trials
– volume: 15
  start-page: 359
  issue: 4
  year: 2018
  end-page: 365
  article-title: How to Construct an Optimal Interim Report: What the Data Monitoring Committee Does and Doesn't Need to Know
  publication-title: Clinical Trials
– year: 2013
– ident: e_1_2_10_14_1
  doi: 10.1007/s43441‐023‐00499‐0
– ident: e_1_2_10_4_1
  doi: 10.1056/NEJMra1510066
– ident: e_1_2_10_12_1
  doi: 10.1177/1740774518764855
– ident: e_1_2_10_29_1
  doi: 10.1177/2168479018754846
– ident: e_1_2_10_15_1
  doi: 10.3310/hta9070
– ident: e_1_2_10_19_1
  doi: 10.1177/1740774518764449
– ident: e_1_2_10_24_1
– ident: e_1_2_10_16_1
  doi: 10.1201/9781315181608
– ident: e_1_2_10_11_1
  doi: 10.1177/1740774516688915
– ident: e_1_2_10_18_1
  doi: 10.1016/j.cct.2020.106154
– ident: e_1_2_10_2_1
  doi: 10.1177/2168479017739268
– ident: e_1_2_10_26_1
– ident: e_1_2_10_3_1
  doi: 10.1177/1740774517707743
– ident: e_1_2_10_20_1
– ident: e_1_2_10_23_1
  doi: 10.1056/NEJMsb1601674
– ident: e_1_2_10_9_1
  doi: 10.7326/M19‐1491
– ident: e_1_2_10_5_1
  doi: 10.1002/0470854162
– ident: e_1_2_10_21_1
  doi: 10.1002/sim.1791
– ident: e_1_2_10_22_1
  doi: 10.1109/VL.1996.545291
– ident: e_1_2_10_17_1
  doi: 10.1001/jama.2016.16070
– ident: e_1_2_10_28_1
  doi: 10.1080/19466315.2020.1736142
– ident: e_1_2_10_10_1
  doi: 10.1056/evidctw2200220
– ident: e_1_2_10_7_1
– ident: e_1_2_10_25_1
– ident: e_1_2_10_6_1
– ident: e_1_2_10_8_1
  doi: 10.1056/evidctw2100005
– ident: e_1_2_10_13_1
  doi: 10.1080/10543406.2014.925719
– ident: e_1_2_10_27_1
  doi: 10.1186/s13063‐023‐07290‐4
SSID ssj0009042
Score 2.3721304
SecondaryResourceType review_article
Snippet ABSTRACT Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor...
Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e202300384
SubjectTerms benefit‐risk
Biometry - methods
Clinical Trials Data Monitoring Committees
data monitoring committee
Displays
Effectiveness
Humans
Monitoring
patient safety
Pharmaceutical industry
Scientific validity
Stakeholder Participation
study integrity
Title Stakeholders' Perspectives on Current Issues in Data Monitoring Committees
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbimj.202300384
https://www.ncbi.nlm.nih.gov/pubmed/39308116
https://www.proquest.com/docview/3116759731
https://www.proquest.com/docview/3108389756
Volume 66
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA8yEHzx-2M6JYKwp25rmn7kUZ1DBxMRB3srSZvCnHbiugf9671r2s4pIuhbSy40zeWS3-WS3xFyFuhExZENvkkCauCxBJsLfGZ5knHFY-0mGu8OD2696yHvj9zRp1v8hh-i2nBDy8jnazRwqWbtBWmoGj8_tjD5Nwa3kBDUdjwkz-_eL_ijRIebMAJzLBDyS9bGDmsvV19elb5BzWXkmi89vQ0iy0abEyeT1jxTrej9C5_jf_5qk6wXuJSem4G0RVZ0uk1WTabKtx3SB1A60RiqArjYpHeLK5ozOk1pwfJETS4_Ok5pV2aSmgkDdw4pXkQZZ5nWs10y7F09XF5bRRoGK4IVjluxnYCPJrQLjrSUvp34gUq4x6QOPDsGJ1cFftRJlCdiDipWQoLehXIidHU8QDx7pJZOU31AKHekjF03igItuHK09HGSYzpIXCaYUnVilWoIo4KjHFNlPIWGXZmF2D9h1T910qzkXww7x4-SjVKrYWGls9DBIJSLybvq5LQqBvvCoIlM9XSOMgBSA-G7Xp3sm9FQfcoRDiAqG0pYrtNf2hBe3Az61dvhXyodkTV45uY0YYPUste5PgZUlKmTfOR_AOEUAlk
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT-MwEB6xILRceC5QnkZaiVPaxnEePvJUKRShFUh7i-zEkcojRTQ9wK9npk5SFYRWWo6Jx4rj8djfeOxvAH5HJtNp4qJvkqEaRKrQ5qKQO4HiQovU-Jmhu8O966BzJ7p__eo0Id2FsfwQ9YYbWcZ4viYDpw3p1oQ1VPef7puU_ZuiW-IHzAlEG-R_nf6ZMEjJtrCBBO45KBVWvI1t3pquP70ufQKb09h1vPicL4Gumm3PnDw0R4VuJm8fGB2_9V_LsFhCU3Zkx9IKzJh8FeZtssrXNegiLn0wFK1CxHjIbia3NIdskLOS6InZdH6sn7NTVShm5wzaPGR0F6VfFMYMf8Hd-dntSccpMzE4CS5ywkndDN00aXz0pZUK3SyMdCYCrkwUuCn6uToKk3amA5kK1LKWClUvtZeQtxMg6FmH2XyQm01gwlMq9f0kiYwU2jMqpHmOmyjzueRaN8Cp9BAnJU05Zct4jC3BMo-pf-K6fxpwWMs_W4KOLyV3KrXGpaEOY4_iUD7l72rAQV2MJkZxE5WbwYhkEKdGMvSDBmzY4VB_ypMegioXS_hYqf9oQ3x80evWT1v_U2kffnZue1fx1cX15TYs4HthDxfuwGzxMjK7CJIKvTc2g3ca6wZ4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED9BEYgX2Pjs6DZPmsRT2sZxPvwIYxV0AyEEEm-RndhS-UgRTR_gr99dnabr0IQEj4nPiuPz2b_z2b8D-J4Yq_PMR9_EohpErtDmkph7keJCi9yE1tDd4dOz6PhK9K_D679u8Tt-iHrDjSxjMl-TgT_ktjMjDdWD-5s2Jf-m4JZYhCURIZwgWHQxI5CSXeHiCDzwUCqe0jZ2eWe-_vyy9AJrzkPXydrTWwc1bbU7cnLbHpe6nT3_Q-j4nt_6AGsVMGUHbiR9hAVTbMCyS1X5tAl9RKW3hmJViBf32fnsjuaIDQtW0Twxl8yPDQp2pErF3IxBW4eMbqIMytKY0RZc9X5e_jj2qjwMXoZLnPBy36KTJk2InrRSsW_jRFsRcWWSyM_Ry9VJnHWtjmQuUMdaKlS81EFGvk6EkGcbGsWwMLvARKBUHoZZlhgpdGBUTLMcN4kNueRaN8GbqiHNKpJyypVxlzp6ZZ5S_6R1_zRhv5Z_cPQc_5VsTbWaVmY6SgOKQoWUvasJ3-piNDCKmqjCDMckg8MqkXEYNWHHjYb6U4EMEFL5WMInOn2lDenhyWm_fvr0lkpfYeX8qJf-Pjn7tQer-Fq4k4UtaJSPY_MZEVKpv0yM4A_4MgUn
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stakeholders%27+Perspectives+on+Current+Issues+in+Data+Monitoring+Committees&rft.jtitle=Biometrical+journal&rft.au=Cartwright%2C+Michael+J.&rft.au=Friede%2C+Tim&rft.au=Lawrence%2C+David&rft.au=May%2C+Emma&rft.date=2024-10-01&rft.issn=0323-3847&rft.eissn=1521-4036&rft.volume=66&rft.issue=7&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fbimj.202300384&rft.externalDBID=10.1002%252Fbimj.202300384&rft.externalDocID=BIMJ202300384
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0323-3847&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0323-3847&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0323-3847&client=summon